Figure 2.

Percentage of patients meeting American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 response criteria after 6 months of therapy with abatacept or placebo. From data presented by Kremer and coworkers [3]. *P ≤ 0.05 versus placebo; ^†P ≤ 0.001 versus placebo.